PRECISE PROTEOMICS
WELCOME TO PRECISE PROTEOMICS
Developing novel precise, accurate and quantitative assays to inform and enable development of curative therapies, with an emphasis on genetic diseases
ABOUT US
With our innovative proprietary mass spectrometry platform, we develop precise, accurate, quantitative assays for proteins in blood, plasma and tissue samples. Founded in 2023, the impact of this approach developed by Dr. Ian Blair has already been shown in curative therapeutic programs for Friedreich's Ataxia (FRDA). The platform can be applied to other genetic diseases to transform the probability of success for the development of curative therapies. Get in touch to learn more.
"Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop questioning."
Albert Einstein